SS&C Technologies Holdings Inc·4

Sep 14, 8:26 PM ET

BOULANGER NORMAND A 4

4 · SS&C Technologies Holdings Inc · Filed Sep 14, 2023

Insider Transaction Report

Form 4
Period: 2023-09-12
BOULANGER NORMAND A
DirectorPresident and COO
Transactions
  • Exercise/Conversion

    Common Stock

    2023-09-12$21.10/sh+170,000$3,587,000400,000 total
  • Sale

    Common Stock

    2023-09-12$55.19/sh20,000$1,103,772380,000 total
  • Sale

    Common Stock

    2023-09-13$54.61/sh40,000$2,184,492340,000 total
  • Sale

    Common Stock

    2023-09-14$55.06/sh60,000$3,303,618280,000 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2023-09-12170,0000 total
    Exercise: $21.10Exp: 2023-12-20Common Stock (170,000 underlying)
Footnotes (4)
  • [F1]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $55.12 to $55.28. The reporting person undertakes, upon request by the Staff of the Securities and Exchange Commission, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F2]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $54.55 to $54.76. The reporting person undertakes, upon request by the Staff of the Securities and Exchange Commission, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F3]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $54.90 to $55.32. The reporting person undertakes, upon request by the Staff of the Securities and Exchange Commission, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  • [F4]The option is a "time-based" option that vested in full on December 20, 2017.

Documents

2 files
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION

  • EX-24

    POA DOCUMENT